News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Skystar Bio-Pharmaceutical (CGPN) Regains NASDAQ Compliance


5/2/2012 8:28:29 AM

XI'AN, CHINA--(Marketwire - May 02, 2012) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that it had received a letter dated May 1, 2012 from Nasdaq Listing Qualifications Hearings stating that the Panel had determined that Skystar has met the requirements of the Panel's decision dated March 26, 2012, and is in compliance with all other applicable requirements for continued listing on the Nasdaq Stock Market. Accordingly, the Panel has determined to continue the listing of the Company's securities on the Nasdaq Stock Market and is closing this matter.

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with, among many others, the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. Please refer to the Company's Annual Report or Form 10-K for the period ended December 31, 2011 filed with the SEC for a full description of various risk factors facing the Company.


Contact:

Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development and U.S. Representative
(407) 645-4433

Grayling
Investor Relations
Christopher Chu
(646) 284-9426
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES